KTKen Takasaki

Ken Takasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ken Takasaki has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 November 2007
      • Vol. 104  (11) , 1601-6

    [Usefulness of transcatheter arterial embolization (TAE) for large hepatocellular carcinoma using a lecithin-added Lipiodol emulsion].

    by Shinjiro Kobayashi, Takehito Otsubo, Satoshi Koizumi, Kenji Yoshitoshi, Satoshi Katagiri, Tatsuya Furukawa, Masakazu Yamamoto, Ken Takasaki

    This study was to retrospectively compare the effectiveness of transarterial embolization (TAE) using a lipidol emulsion for large lesion of hepatocellular carcinoma (HCC). average survival time was retrospectively compared in patients with HCC larger then 3 cm in diameter. Twenty patients were treated with conventional transarterial embolization (TAE)(group A), 27 with transarterial embolization using a lipidol emulsion (TAE-L) (group B). Rates of effectiveness at 3 months and 6 months following treatment were 10.0% and 5.0% in group A and 37.0 and 33.3% in group B respectively (P=0.046, 0.029). The median survival times were 12.0 months in Group A and 23.0 months in Group B (P=0.049).

    • 1 September 2007
      • Vol. 34  (9) , 1433-7

    [Usefulness of hepatic arterial infusion chemotherapy using lecithin-added lipiodol emulsion in hepatocellular carcinoma].

    by Shinjiro Kobayashi, Satoshi Koizumi, Satoshi Katagiri, Shunichi Ariizumi, Yutaka Takahashi, Takehito Otsubo, Ken Takasaki, Masakazu Yamamoto

    After implanting a reservoir in the hepatic artery, we performed intra-arterial chemotherapy with a smaller particle size lipiodol emulsion and examined its therapeutic effect. Subjects were 21 patients with advanced/recurrent hepatocellular carcinoma (HCC). Arterial infusion was performed once every 2 weeks on an outpatient basis using 2 mL lipiodol emulsion with lecithin added as a surface active agent and 10 mg doxorubicin hydrochloride. As of 6 months after the start of treatment, the response rate was 38.1%. Median survival was 17.0 months. Serious adverse events were not noted in any of the subjects;during the course of treatment, catheter occlusion was observed in 2 patients. This therapy allows fewer visits and provides a relatively substantial therapeutic effect while maintaining QOL, so it may serve as an effective treatment for highly advanced/multiple HCC not suited to other treatments.

    • 11 April 2007
      • Vol. 54  (73) , 210-3

    Liver metastases with massive portal venous tumor thrombi from colorectal cancer: can be treated by surgical resection?

    by Taizen Urahashi, Masakazu Yamamoto, Takehito Ohtsubo, Hideo Katsuragawa, Satoshi Katagiri, Ken Takasaki

    The surgical treatments for liver metastases from colorectal cancer with massive portal venous tumor thrombi were evaluated. Five patients, among the 142 patients who underwent hepatic resection for liver metastases from colorectal cancer from 1989 to 1998, were included in this study. The tumor thrombi in the main portal vein were removed by the following procedures; (1) the circumferential incision of the first branch of the portal vein and removal of the exposed tumor thrombi with ring forceps and suction, (2) temporary clamping of the distal end, (3) dilatation of the round ligament and the venous cannula was inserted into the umbilical portion, (4) washing out of the residual tumor thrombi, (5) declamping of the distal end and closing suture of the cut end of the portal branch. All patients had metachronous metastases and underwent resections of the primary tumor within 2 years. The surgical procedures performed were as follows: two cases that underwent right hepatectomies with portal venous tumor thrombectomies, one right trisectionectomy with portal venous tumor thrombectomy, one right hepatectomy plus limited resection of the contralateral lobe, and one left lateral sectionectomy with limited resection of the right lobe. All patients had no major postoperative complications and returned to their social lives within 1 month after operation. The intra-arterial catheter devices were implanted in four patients in order to receive adjuvant chemotherapy. One patient survived the 36-month period after liver resection, although 4 patients died of liver recurrence within 12 months. The mean survival time was 14.4 months and the overall 1-year survival rate was 20.0 percent. Surgical resection for this disease may bring longer survival rates for some patients, but not be an effective therapeutic option in our series. We should create other adjuvant therapies to improve these survival rates.


    • 1 March 2007
      • Vol. 54  (74) , 346-9

    Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma.

    by Taizen Urahashi, Masakazu Yamamoto, Takehito Ohtsubo, Hideo Katsuragawa, Satoshi Katagiri, Ken Takasaki

    Patients with advanced intrahepatic cholangiocarcinoma (ICC) have a poor outcome even if they undergo extended radical surgery. Hepatopancreatoduodenectomy (HPD; hepatectomy with pancreatoduodenectomy) for ICCs may be expected to provide a favorable outcome if curative resection is reasonable and patients can tolerate the radical major procedure. Between January 1981 and March 2002, 152 hepatic resections were performed for ICC. Of these, 12 patients underwent HPD for ICC at the same institute of Gastroenterology, Tokyo Women's Medical University. HPD for ICC was indicated in patients who (1) require dissection of the peripancreatic lymph nodes, (2) exhibit direct invasion of intrapancreatic bile duct, (3) show signs of intrapancreatic bile ductal growth. Characteristics of the short-term survivors (died within 12 months), compared with long-term survivors (survived more than 12 months), indicated that they were more likely to be positive intrahepatic metastasis, to be positive lymph node metastasis, to be positive portal venous invasion, and margins of resected surface with residual tumor. The actuarial overall 1-, 3-, 5-, 10-year survival rates were 42%, 33%, 33%, and 23%, respectively. The 5-year survival rate in patients without lymph node metastasis was significantly better (p = 0.045) than that of patients with lymph node metastasis. The patients who underwent potentially curative resection had significantly better 5-year survival rates than those who underwent non-curative resection. Four patients survived for at least 5 years and two of these patients survived for more than 10 years. Nine patients developed recurrence after resection, and of these, 5 patients with recurrence died within 12 months after surgery. HPD is considered to be an efficacious procedure for advanced ICC and long-term survival may be possible in a selected group of patients.


  • A Case of Shwannoma of the Rectum

    by Kenichiro Imai, Yuji Inoue, Takehiro Ota, Masakazu Yamamoto, Ken Takasaki

    • 17 April 2004
      • Vol. 51  (56) , 500-4

    Histopathologic differentiation of the main nodule determines outcome after hepatic resection for synchronous multicentric hepatocellular carcinomas.

    by Shun-Ichi Ariizumi, Ken Takasaki, Masakazu Yamamoto, Takehito Ohtsubo, Hideo Katsuragawa, Satoshi Katagiri

    Clinicopathological features and outcome after surgery in patients with synchronous multicentric hepatocellular carcinoma were examined in relation to the histopathological grade of differentiation of the main nodule. Two hundred and sixty-five patients with synchronous multicentric hepatocellular carcinoma (total, 683 nodules) who had undergone curative hepatectomy from 1988 through 1999 were studied retrospectively. In multicentric occurrences of hepatocellular carcinoma, the tumor with the largest dimension was defined as the main nodule, and the others as accessory nodules. The histopathological grade of differentiation of the main nodule was assessed to be well differentiated in 72 patients (27.2%), moderately differentiated in 160 patients (60.4%), and poorly differentiated in 33 patients (12.4%). Tumor size of the main nodule was significantly smaller in patients with well differentiated hepatocellular carcinoma than in patients with moderately or poorly differentiated hepatocellular carcinoma. Alpha-fetoprotein levels were significantly lower in cases in which the main nodule was diagnosed to be well differentiated hepatocellular carcinoma than in other cases. The 5-year survival rate and recurrence-free survival rate were significantly greater in cases in which the main nodule showed well differentiated hepatocellular carcinoma (78.1% and 33.8%, respectively) than in other cases [moderately differentiated 49.0% (p<0.0001), 11.6% (P=0.0002); poorly differentiated 37.4% (p<0.0001), 8.3% (P=0.0002), respectively]. Multivariate analysis identified the histopathological grade of the main nodule as significant independent prognostic factors. There were differences in surgical outcome in relation to the histopathological grade of differentiation of the main nodule in patients with synchronous multicentric hepatocellular carcinoma.


  • Open Access

    Clinical significance of the high density ring at the circumference of hepatocellular carcinoma on abdominal contrast computed tomography

    by Satoshi Koizumi, Takehito Otsubo, Masakazu Yamamoto, Kenji Yoshitoshi, Ken Takasaki